# Johnson & Johnson (NYSE: JNJ)

### Accounting Year End: 2023-01-01

Here is a summary of the key sections from Johnson & Johnson's 10-K filing:

Executive Summary:

- Johnson & Johnson is a global healthcare company operating in three segments: Consumer Health, Pharmaceutical, and MedTech. Key products include Tylenol, Neutrogena, Remicade, Stelara, and medical devices for orthopedics, surgery and vision.  
- The company generates significant revenue internationally, faces competitive and regulatory pressures, and is involved in major legal proceedings related to talc, opioids, and more.
- Johnson & Johnson plans to separate its Consumer Health business into a new publicly traded company called Kenvue.
- Overall the tone of the 10-K is neutral, providing a factual overview of the business, risks, and legal matters. There are some cautious notes regarding competitive threats, regulations, and legal issues.

Business:

- Operates in three segments: Consumer Health, Pharmaceutical, and MedTech
- Key Consumer brands: Tylenol, Neutrogena, Listerine, Aveeno
- Key Pharma products: Remicade, Stelara, Xarelto, Darzalex
- Key MedTech products: orthopedic, surgery, and vision devices
- Competes in all product lines globally 
- Invests significantly in R&D and product development
- 49% of sales from international markets in 2022
- Plans to separate Consumer Health into a new public company called Kenvue

Sentiment: Neutral (0.02) - Factual overview of business units and competitive landscape.

Risk Factors:

- Faces significant competition in all business segments
- Reliant on third party manufacturers for some products
- Global health crises like COVID-19 can impact operations and financial results
- Subject to extensive government regulation and legal proceedings 
- Intellectual property challenges are increasing
- New product development has inherent risks and uncertainties
- International business exposes company to financial, legal and regulatory risks
- Climate change and ESG factors pose risks
- Cybersecurity threats could negatively impact business and reputation
- Risks associated with planned separation of Consumer Health business

Sentiment: Negative (-0.73) - Cautious tone regarding competitive, regulatory, legal, product development, and macroeconomic risks.

Management's Discussion and Analysis:

- Revenue increased 1.3% in 2022 driven by volume growth of 6.9%
- Pharmaceutical segment sales up 1.7%, Consumer Health down 0.5%, MedTech up 1.4%
- International sales were 49% of total in 2022
- R&D expense was 15.4% of sales in 2022
- Net earnings of $17.9 billion in 2022
- Cash flow from operations was $21.2 billion in 2022
- Plans to separate Consumer Health business into new public company Kenvue

Sentiment: Neutral (0.02) - Largely factual discussion of financial performance.

Legal Proceedings:

- Involved in various lawsuits and claims related to product liability, intellectual property, and other matters
- Government investigations and proceedings related to marketing, pricing, and regulatory compliance
- Details provided in Note 19 to the financial statements

Sentiment: Negative (-0.73) - Cautious tone regarding extent of legal matters.

Accounting Policies and Estimates:

- No changes in accounting policies or disagreements with accountants to report

Sentiment: Neutral (0.00)

Change in Business Over Prior Two Years:

- Revenue growth slowed from 13.6% in 2021 to 1.3% in 2022
- Net earnings declined from $20.9 billion in 2021 to $17.9 billion in 2022
- R&D spend has remained steady at 15.4% of sales in 2022 vs 15.7% in 2021
- Pharmaceutical growth slowed from 14.3% in 2021 to 1.7% in 2022
- MedTech growth slowed from 17.9% in 2021 to 1.4% in 2022 
- Consumer Health declined 0.5% in 2022 after growing 4.1% in 2021
- Cash from operations declined from $23.4 billion in 2021 to $21.2 billion in 2022
- Legal proceedings related to opioids have declined while talc litigation has increased

Sentiment: Negative (-0.45) - Growth has slowed while legal issues persist.